Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Journal of Pharmaceutical and Biomedical Analysis
|
December 18, 2007
A quality by design approach to impurity method development for atomoxetine hydrochloride (LY139603)
Peter F Gavin, Bernard A Olsen
Advanced Drug Delivery Reviews
|
December 27, 2006
Strategies for the investigation and control of process-related impurities in drug substances
Mark D Argentine, Paul K Owens, Bernard A Olsen
Journal of Pharmaceutical and Biomedical Analysis
|
June 2, 2007
Is HPLC assay for drug substance a useful quality control attribute?
Jeffrey D Hofer, Bernard A Olsen, Eugene C Rickard
Journal of Pharmaceutical and Biomedical Analysis
|
April 20, 2006
A quality evaluation strategy for multi-sourced active pharmaceutical ingredient (API) starting materials
Peter F Gavin, Bernard A Olsen, David D Wirth, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
March 15, 2006
Determination of the enantiomer and positional isomer impurities in atomoxetine hydrochloride with liquid chromatography using polysaccharide chiral stationary phases
Jane A Sellers, Bernard A Olsen, Paul K Owens, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
March 30, 2016
Formation of copper(I) from trace levels of copper(II) as an artifactual impurity in the HPLC analysis of olanzapine
Steven W Baertschi, Bernard A Olsen, Timothy J Wozniak, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
February 3, 2009
A simple and efficient approach to reversed-phase HPLC method screening
Kallol M Biswas, Bryan C Castle, Bernard A Olsen, et al.
Talanta
|
April 21, 2009
A new statistical method for the automated detection of peaks in UV-DAD chromatograms of a sample mixture
Benjamin Debrus, Pierre Lebrun, Attilio Ceccato, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Journal of Pharmaceutical and Biomedical Analysis
|
December 18, 2007
A quality by design approach to impurity method development for atomoxetine hydrochloride (LY139603)
Peter F Gavin, Bernard A Olsen
Advanced Drug Delivery Reviews
|
December 27, 2006
Strategies for the investigation and control of process-related impurities in drug substances
Mark D Argentine, Paul K Owens, Bernard A Olsen
Journal of Pharmaceutical and Biomedical Analysis
|
June 2, 2007
Is HPLC assay for drug substance a useful quality control attribute?
Jeffrey D Hofer, Bernard A Olsen, Eugene C Rickard
Journal of Pharmaceutical and Biomedical Analysis
|
April 20, 2006
A quality evaluation strategy for multi-sourced active pharmaceutical ingredient (API) starting materials
Peter F Gavin, Bernard A Olsen, David D Wirth, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
March 15, 2006
Determination of the enantiomer and positional isomer impurities in atomoxetine hydrochloride with liquid chromatography using polysaccharide chiral stationary phases
Jane A Sellers, Bernard A Olsen, Paul K Owens, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
March 30, 2016
Formation of copper(I) from trace levels of copper(II) as an artifactual impurity in the HPLC analysis of olanzapine
Steven W Baertschi, Bernard A Olsen, Timothy J Wozniak, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
February 3, 2009
A simple and efficient approach to reversed-phase HPLC method screening
Kallol M Biswas, Bryan C Castle, Bernard A Olsen, et al.
Talanta
|
April 21, 2009
A new statistical method for the automated detection of peaks in UV-DAD chromatograms of a sample mixture
Benjamin Debrus, Pierre Lebrun, Attilio Ceccato, et al.
Page
of 1